US Stock MarketDetailed Quotes
FHTX Foghorn Therapeutics
- 5.490
- +0.260+4.97%
Close Apr 26 16:00 ET
233.69MMarket Cap-2346P/E (TTM)
5.545High5.160Low35.37KVolume5.250Open5.230Pre Close191.73KTurnover0.17%Turnover RatioLossP/E (Static)42.57MShares9.97052wk High-3.03P/B117.19MFloat Cap2.70052wk Low--Dividend TTM21.35MShs Float28.265Historical High--Div YieldTTM7.36%Amplitude2.700Historical Low5.421Avg Price1Lot Size
Foghorn Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -161.00%-118.11M | 4.78%-27.54M | -36.15%-27.21M | -10.90%-32.18M | -111.48%-31.18M | 485.30%193.61M | -343.43%-28.92M | 2.52%-19.99M | -56.97%-29.01M | 1,273.09%271.53M |
| Net income from continuing operations | 9.60%-98.43M | 16.55%-24.11M | 44.33%-14.35M | -7.96%-29.49M | -13.28%-30.49M | -7.46%-108.88M | 0.88%-28.89M | 1.19%-25.77M | -18.18%-27.31M | -17.09%-26.91M |
| Operating gains losses | -50.00%3K | --0 | ---- | ---- | ---- | -99.51%6K | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 3.91%3.45M | 0.47%852K | 2.49%864K | 6.96%876K | 5.92%859K | 2.91%3.32M | 4.69%848K | -2.09%843K | 4.46%819K | 5.05%811K |
| Other non cash items | 13.76%5.21M | -32.61%1.4M | 411.58%1.33M | 13.46%1.29M | 7.72%1.2M | -0.56%4.58M | 80.31%2.07M | -76.96%259K | -4.21%1.14M | -2.88%1.11M |
| Change In working capital | -114.87%-41.88M | -33.54%-8.24M | -1,516.23%-18.5M | -25.76%-8.59M | -102.23%-6.55M | 741.92%281.55M | -117.30%-6.17M | 16.30%1.31M | -1,201.94%-6.83M | 7,514.44%293.24M |
| -Change in receivables | --0 | --0 | --0 | --0 | --0 | 200.00%300M | --0 | --0 | --0 | --300M |
| -Change in prepaid assets | 341.37%741K | 59.56%-556K | -39.50%671K | -16.00%-261K | 382.07%887K | 83.08%-307K | 35.45%-1.38M | 175.19%1.11M | -208.17%-225K | 162.37%184K |
| -Change in payables and accrued expense | -131.13%-951K | -90.87%96K | -93.05%252K | -139.54%-836K | 63.57%-463K | 9.58%3.06M | -55.82%1.05M | 53.11%3.62M | -124.84%-349K | 62.21%-1.27M |
| -Change in other current liabilities | -7.73%-7.51M | -20.88%-2.01M | -8.25%-1.94M | -7.24%-1.9M | 4.79%-1.67M | -73.94%-6.98M | 1.01%-1.66M | -11.64%-1.79M | -147.62%-1.77M | -15,827.27%-1.75M |
| -Change in other working capital | -140.07%-34.16M | -37.92%-5.77M | -969.65%-17.48M | -24.70%-5.6M | -35.43%-5.31M | -104.23%-14.23M | -101.24%-4.18M | -3,885.37%-1.63M | -1,509.32%-4.49M | -1,270.63%-3.92M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -161.00%-118.11M | 4.78%-27.54M | -36.15%-27.21M | -10.90%-32.18M | -111.48%-31.18M | 485.30%193.61M | -343.43%-28.92M | 2.52%-19.99M | -56.97%-29.01M | 1,273.09%271.53M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 159.12%144.45M | 674.54%37.39M | -16.56%38.43M | 131.44%39.13M | 118.51%29.51M | -775.43%-244.32M | -167.27%-6.51M | 197.30%46.05M | -261.45%-124.46M | -4,788.35%-159.41M |
| Net PPE purchase and sale | -1.16%-1.22M | 85.87%-38K | 75.45%-81K | -28.85%-469K | -157.49%-636K | 63.48%-1.21M | -236.25%-269K | -43.48%-330K | 69.89%-364K | 86.23%-247K |
| Net investment purchase and sale | 159.92%145.67M | 699.92%37.42M | -16.98%38.51M | 131.91%39.6M | 118.94%30.14M | -715.69%-243.11M | -163.96%-6.24M | 198.48%46.38M | -258.49%-124.09M | -10,749.49%-159.16M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 159.12%144.45M | 674.54%37.39M | -16.56%38.43M | 131.44%39.13M | 118.51%29.51M | -775.43%-244.32M | -167.27%-6.51M | 197.30%46.05M | -261.45%-124.46M | -4,788.35%-159.41M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0.85%1.78M | 1,062.50%186K | 316.52%1.39M | -90.00%103K | -73.44%102K | -92.14%1.76M | -99.93%16K | -34.06%333K | 827.93%1.03M | 519.35%384K |
| Proceeds from stock option exercised by employees | 0.85%1.78M | 1,062.50%186K | 316.52%1.39M | -90.00%103K | -73.44%102K | 24.33%1.76M | -97.84%16K | -34.06%333K | 827.93%1.03M | 519.35%384K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 0.85%1.78M | 1,062.50%186K | 316.52%1.39M | -90.00%103K | -73.44%102K | -92.14%1.76M | -99.93%16K | -34.06%333K | 827.93%1.03M | 519.35%384K |
| Net cash flow | ||||||||||
| Beginning cash position | -47.58%53.92M | -19.39%72.01M | -5.61%59.41M | -75.69%52.35M | -47.58%53.92M | 8.82%102.87M | 49.96%89.34M | -50.40%62.94M | 215.89%215.38M | 8.82%102.87M |
| Current changes in cash | 157.45%28.12M | 128.32%10.03M | -52.26%12.6M | 104.63%7.06M | -101.40%-1.57M | -686.82%-48.95M | -181.80%-35.42M | 139.21%26.4M | -359.62%-152.44M | 527.04%112.51M |
| End cash Position | 52.15%82.04M | 52.15%82.04M | -19.39%72.01M | -5.61%59.41M | -75.69%52.35M | -47.58%53.92M | -47.58%53.92M | 49.96%89.34M | -50.40%62.94M | 215.89%215.38M |
| Free cash flow | -162.02%-119.33M | 5.53%-27.58M | -34.34%-27.29M | -11.12%-32.64M | -111.73%-31.82M | 459.21%192.4M | -347.36%-29.19M | 2.01%-20.32M | -49.18%-29.38M | 1,187.72%271.29M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg